Global Genome Editing Market Forecast to 2025
- March, 2019
- Domain: Healthcare - Biotechnology
Pages:
97
Tables:
30
Charts:
42
Regions/Countries:
4 / 0
Companies:
12
Enquiry Hours:
10
- Get Free 10% Customization in this Report
[98 pages report] This market research report includes a detailed segmentation of the global genome editing market – by technology (CRISPR, TALEN, ZFN, and Others), by application (Cell Line Engineering, Genetic Engineering, and Others), By end-user (Research Institutes, Biotechnology and Pharmaceutical Companies, and Contract Research Organizations), by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Genome Editing Market
Infoholic’s market research report predicts that the “Global Genome Editing Market” will grow at a CAGR of 14.4% during the forecast period. The market has witnessed steady growth in the past few years with the development in technology and the introduction of highly sensitive, robust, and reliable systems in the market. The market is fueled due to increase in genetic disorders, increasing investment and funds, and technological advancements in genome editing.
The market continues to grow and is one of the increasingly accepted market in many countries worldwide. Vendors are focusing towards obtaining funds and collaborating with universities to enlarge their research and development capabilities. The majority of the revenue is generated from the leading players in the market with dominating sales of ThermoFisher Scientific, GenScript Corp., Sangamo Therapeutics, Lonza Group, and Horizon Discovery Group plc.
According to Infoholic Research analysis, North America accounted for the largest share of the global genome editing market in 2018. US dominates the market with majority of genome editing companies being located in this region. However, China has not been too far behind and has great government support for the research in genome editing field.
Genome Editing Market by Technology:
- CRISPR
- TALEN
- ZFN
- Others
In 2018, the CRISPR segment occupied the largest share due to specific, effective, and cost-effective nature of the technology. Many companies are focusing on providing genome editing services. For instance, in January 2019, Horizon Discovery extended CRISPR screening service to primary human T cells.
Genome Editing Market by Applications:
- Cell Line Engineering
- Genetic Engineering
- Others
In 2018, the cell line engineering accounted the maximum share followed by genetic engineering. Increase in the number of people suffering with genetic disorders has driven the growth of the genome editing market.
Genome Editing Market by End Users:
- Research Institutes
- Biotechnology and Pharmaceutical Companies
- Contract Research Organizations
In 2018, the biotechnology and pharmaceutical companies gained the highest market share for genome editing market due to increased pervasiveness of cancer and infectious diseases are driving research goings-on in biotechnology & pharmaceutical companies segment.
Genome Editing Market by Regions:
- North America
- Europe
- APAC
- ROW
The market is dominated by North America, followed by Asia Pacific and Europe. The major share of the North America market is from the US due to quick adoption of new and advanced technologies.
Genome Editing Market Research Competitive Analysis – The market is extremely fragmented with several smaller companies struggling for market share. Big pharmaceutical establishments have also united with venture capitalists to provide funding to the start-ups. In 2015, Bayer financed $335 million and in the very same year, Celgene combined with Abingworth invested $64 million in CRISPR Therapeutics. The NIH recently granted 21 somatic cell genome editing grants of almost $86 million over the next half a decade. These endowments are the foremost to be granted through the Somatic Cell Genome Editing (SCGE) program that was initiated in January 2018 with NIH Common Fund.
The companies are collaborating and licensing to increase their capabilities in the market. CRISPR, TALEN, ZFN, Meganuclease, ARCUS, and RTDS are some of the key technology areas concentrated by key players in the market. Since 2015, the deals on the CRISPR technology has drastically increased.
Key vendors:
- ThermoFisher Scientific
- GenScript Corp.
- Sangamo Therapeutics
- Lonza Group
- Horizon Discovery Group plc
- Merck KGaA
- Transposagen Biopharmaceutical
- CRISPR Therapeutics
- Editas Medicine
- Integrated DNA Technologies
- New England Biolabs
- Origene Technologies, Inc.
Key competitive facts –
- Genetic editing technologies are intensely evolving from previous two decades and has facilitated in the variation of genome further rapidly and in a less expensive technique.
- The US is the leader in the CRISPR technology, while the market for TALEN genome editing technology is dominated by China.
Benefits – The report provides complete details about the usage and adoption rate of genome editing market. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the healthcare segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
- Understanding the potential market opportunity with precise market size and forecast data
- Detailed market analysis focusing on the growth of genome editing industry
- Factors influencing the growth of genome editing market
- In-depth competitive analysis of dominant and pureplay vendors
- Prediction analysis of genome editing market in both developed and developing regions
- Key insights related to major segments of the genome editing market
- Latest market trend analysis impacting the buying behavior of the consumers
Key Stakeholders
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
1.2.1 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Genetic Testing
3.4.1.1 Trends of the genetic testing market
3.4.2 Liquid Biopsy Market
3.4.2.1 Trends of Liquid biopsy market
3.4.3 Next-generation sequencing
3.4.3.1 Trends in the Next-generation sequencing market
4 Market Outlook
4.1 Funding Scenario
4.2 International Patent Classification (IPC) Codes and for the Technology Areas
4.2.1 Life Science Research
4.2.2 General Research
4.3 Deals
4.4 Porter 5 (Five) Forces
5 Market Characteristics
5.1 Evolution
5.2 Market Segmentation
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Increase in Genetic Disorders
5.3.1.2 Increasing Investment and Funds
5.3.1.3 Technological Advancements in Genome Editing
5.3.2 Restraints
5.3.2.1 Ethical Concerns Associated to Genetic Editing
5.3.2.2 High Cost of Genome Engineering Technologies
5.3.3 Opportunities
5.3.3.1 Market Expansion Opportunities in Emerging Nations
5.3.3.2 Growing Collaboration for Genome Engineering Technologies
5.3.4 DRO – Impact Analysis
5.4 Key Stakeholders
6 Technology Types: Market Size and Analysis
6.1 Overview
6.2 CRISPR/Clustered Regularly Interspaced Short Palindromic Repeats
6.3 TALEN/Transcription Activator-Like Effector Nuclease
6.4 ZFN/Zinc-Finger Nucleases
6.5 Others
7 Application Types: Market Size and Analysis
7.1 Overview
7.2 Cell Line Engineering
7.3 Genetic Engineering
7.4 Others
8 End Users: Market Size and Analysis
8.1 Overview
8.2 Research Institutes
8.3 Biotechnology and Pharmaceutical Companies
8.4 Contract Research Organizations
9 Regions: Market Size and Analysis
9.1 Overview
9.2 North America
9.2.1 Overview
9.3 Europe
9.3.1 Overview
9.4 Asia Pacific
9.4.1 Overview
9.5 Rest of the World
9.5.1 Overview
10 Competitive Landscape
11 Vendors Profile
11.1 ThermoFisher Scientific, Inc.
11.1.1 Overview
11.1.2 Business Units
11.1.3 Geographic Presence
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategy
11.2 GenScript Corp.
11.2.1 Overview
11.2.2 Business Units
11.2.3 Geographic Presence
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 SANGAMO THERAPEUTICS, INC.
11.3.1 Overview
11.3.2 Business Focus
11.3.3 SWOT Analysis
11.3.4 Business Strategies
11.4 Lonza Group
11.4.1 Overview
11.4.2 Business Units
11.4.3 Geographic Presence
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategies
11.5 Horizon Discovery Group plc
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Presence
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategies
12 Companies to Watch for
12.1 Merck KGaA
12.1.1 Overview
12.2 Transposagen Biopharmaceuticals
12.2.1 Overview
12.3 CRISPR Therapeutics
12.3.1 Overview
12.4 Editas Medicine
12.4.1 Overview
12.5 Integrated DNA Technologies
12.5.1 Overview
12.6 New England Biolabs
12.6.1 Overview
12.7 Origene Technologies, Inc.
12.7.1 Overview
Annexure
Acronyms
TABLE 1 DEALS BETWEEN 2011–2016 23
TABLE 2 GENOME EDITING MARKET REVENUE, BY TECHNOLOGY TYPE, 2018–2025 ($MILLION) 37
TABLE 3 GENOME EDITING MARKET REVENUE, BY APPLICATION TYPE, 2018-2025 ($MILLION) 44
TABLE 4 GENOME EDITING MARKET REVENUE, BY PRODUCT TYPE, 2018–2025 ($MILLION) 55
TABLE 5 COST COMPARISION OF GENOME EDITING TECHNOLOGY 60
TABLE 6 KEY DEVELOPMENTS IN THE MARKET 61
TABLE 7 THERMO FISHER SCIENTIFIC: PRODUCT OFFERINGS 65
TABLE 8 THERMO FISHER SCIENTIFIC: RECENT DEVELOPMENTS 66
TABLE 9 GENSCRIPT CORPORATION: PRODUCT OFFERINGS 71
TABLE 10 GENSCRIPT CORPORATION: RECENT DEVELOPMENTS 71
TABLE 11 SANGAMO THERAPEUTICS, INC.: PRODUCT OFFERINGS 76
TABLE 12 SANGAMO THERAPEUTICS, INC.: RECENT DEVELOPMENTS 76
TABLE 13 LONZA GROUP: OFFERINGS 79
TABLE 14 LONZA GROUP: RECENT DEVELOPMENTS 79
TABLE 15 HORIZON DISCOVERY GROUP PLC: OFFERINGS 84
TABLE 16 HORIZON DISCOVERY GROUP PLC: RECENT DEVELOPMENTS 84
TABLE 17 MERCK KGAA: SNAPSHOT 90
TABLE 18 MERCK KGAA: RECENT DEVELOPMENTS 90
TABLE 19 TRANSPOSAGEN BIOPHARMACEUTICALS: SNAPSHOT 91
TABLE 20 TRANSPOSAGEN BIOPHARMACEUTICALS: RECENT DEVELOPMENTS 91
TABLE 21 CRISPR THERAPEUTICS: OVERVIEW 92
TABLE 22 CRISPR THERAPEUTICS: RECENT DEVELOPMENTS 92
TABLE 23 EDITAS MEDICINE: OVERVIEW 93
TABLE 24 EDITAS MEDICINE: RECENT DEVELOPMENTS 93
TABLE 25 INTEGRATED DNA TECHNOLOGIES: SNAPSHOT 94
TABLE 26 INTEGRATED DNA TECHNOLOGIES: RECENT DEVELOPMENTS 94
TABLE 27 NEW ENGLAND BIOLABS: OVERVIEW 95
TABLE 28 NEW ENGLAND BIOLABS: RECENT DEVELOPMENTS 95
TABLE 29 ORIGENE TECHNOLOGIES, INC.: OVERVIEW 96
TABLE 30 ORIGENE TECHNOLOGIES, INC.: RECENT DEVELOPMENTS 96
Research Framework
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
- Forecasting
Market related information is congregated from both primary and secondary sources.
Primary sources
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.
